Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GN-604
- Development stage
- Preclinical
- Lead developer
- Southeast University
01
Overview
GN-604: sourced facts only. name: "GN-604 selectively inhibits palmitoyl-protein thioesterase 1 (PPT1) both in vitro and in vivo, leading to lysosomal dysfunction and autophagy inhibition." [PMID:42008866]; target: "GN-604 selectively inhibits palmitoyl-protein thioesterase 1 (PPT1) both in vitro and in vivo, leading to lysosomal dysfunction and autophagy inhibition." [PMID:42008866]; developer: "Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China." [PMID:42008866]; stage: "In vivo evaluations utilizing a MDA-MB-231 xenograft model demonstrated that GN-604 achieved superior antitumor potency to GNS561, cisplatin, or their co-administration." [PMID:42008866]
02
Targets
PPT1 (Palmitoyl-protein thioesterase 1)
Beyond the preview
Go deeper on GN-604.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GN-604.